Dec 13 2024 9 mins
Visit https://www.peervoice.com/RBQ860 to view the entire programme with slides. After completing “Linda Lee, MD, FRCPC / Jacob Rullo, MD, PhD, FRCSC - Managing MEK-Inhibitor–Associated Retinopathy in Metastatic Melanoma: An Expert Discussion”, participants will be able to: Describe the incidence and underlying pathophysiology of MEK-inhibitor—associated serous retinopathy (MEKAR) in metastatic melanoma; Explain optimal monitoring approaches for MEKAR and how to counsel patients on self-monitoring and reporting of symptoms; and Discuss effective management strategies for MEKAR, including when and how to refer to an ophthalmologist to optimize care.